Patrice Bruscella1*
Silvia Bottini2
Camille Baudesson1
Jean-Michel Pawlotsky1Cyrille Feray1
Michele Trabucchi2*- 1INSERM U955, Team “Pathophysiology and Therapy of Chronic Viral Hepatitis”, Université Paris-Est, Créteil, France
- 2INSERM, C3M, Université Côte d’Azur, Nice, France
There is evidence that eukaryotic miRNAs (hereafter called host miRNAs) play a role in the replication and propagation of viruses. Expression or targeting of host miRNAs can be involved in cellular antiviral responses. Most times host miRNAs play a role in viral life-cycles and promote infection through complex regulatory pathways. miRNAs can also be encoded by a viral genome and be expressed in the host cell. Viral miRNAs can share common sequences with host miRNAs or have totally different sequences. They can regulate a variety of biological processes involved in viral infection, including apoptosis, evasion of the immune response, or modulation of viral life-cycle phases. Overall, virus/miRNA pathway interaction is defined by a plethora of complex mechanisms, though not yet fully understood. This article review summarizes recent advances and novel biological concepts related to the understanding of miRNA expression, control and function during viral infections. The article also discusses potential therapeutic applications of this particular host–pathogen interaction.
Background
To date, different classes of regulatory small-RNAs have been identified which differ in their biogenesis, length, and tissue distribution (Ghildiyal and Zamore, 2009; Kim et al., 2009). Among the small RNAs are microRNAs (miRNAs). miRNAs are involved in the control of a broad range of cellular activities, such as development, immune function, and cell death (Sayed and Abdellatif, 2011). Genes can encode single miRNAs or clusters of two or more miRNAs, which are processed from common primary transcripts, called pri-miRNAs (Lee et al., 2004). The pri-miRNAs are processed by the nuclear RNAse III endonuclease DROSHA to generate intermediate precursors of about 70 nucleotides (nt) in length, named pre-miRNAs. The pre-miRNAs are further processed by the cytoplasmic RNAse III endonuclease Dicer to generate mature miRNAs of about 22 nt in length. Proteomic analyses revealed the presence of several RNA-binding proteins that regulate miRNA biogenesis (Gregory et al., 2006; Guil and Caceres, 2007; Trabucchi et al., 2009; Suzuki et al., 2011) in both physiological and pathological contexts (Frezzetti et al., 2011; Abdelmohsen et al., 2012; Repetto et al., 2012; Emde et al., 2015; Hata and Lieberman, 2015).
Mature miRNAs are loaded into Argonaute proteins (mainly AGO2) to form the miRNA-induced silencing complex (miRISC) (Ha and Kim, 2014). One strand of the mature miRNA (the guide strand) targets mRNAs to promote degradation or translational blockade in the Processing-Bodies (Kulkarni et al., 2010). Canonically, miRNAs target the 3′ untranslated region (3′-UTR) or the coding sequence (CDS) of mRNAs by base pairing with nucleotides 2–7 of the miRNA 5′ end, which is called the seed-sequence (Lewis et al., 2003, 2005; Brennecke et al., 2005; Friedman et al., 2009; Pasquinelli, 2012). Some studies claim, however, that about 60% of miRNA binding activity is non-canonical, and involves portions of miRNA sequences located outside of the seed and/or with seed-like motifs including mismatches or bulges (Chi et al., 2012; Helwak et al., 2013).
MicroRNAs were shown to play a role in the replication and propagation of viruses, including cellular antiviral responses and/or in the promotion of viral infections through complex regulatory pathways. It was also shown that miRNAs encoded by viral genomes can be expressed in host cells and participate in the lifecycle and in the cellular consequences of infection. This article review focuses on recent advances in the understanding of miRNA expression and function during viral infections, aiming at providing insights into their role in the pathogenesis of these infections. The article also discusses future directions for research and clinical use of miRNAs as antiviral agents.
Viruses Induce Host miRNAs and Regulate their Turnover and Function
In early phases of viral infections, innate sensors of host cells detect viral products and initiate signal cascades involved in the antiviral responses. Antiviral miRNAs are components of this response. Some viruses have the capacity of manipulating host miRNAs into escaping an antiviral response or to promote viral infection.
Viral Infections Can Induce the Transcription of Host miRNAs Involved in the Antiviral Response
To initiate and maintain an antiviral innate response while the more specific adaptive response takes place, cells have developed a microbial pathogen recognition system based on pathogen recognition receptors (PRRs). PRRs, which include Toll-like receptors (TLRs), retinoic acid-inducible gene I-like receptors and Nod-like receptors, recognize a broad spectrum of motifs common to viral pathogens and this recognition activates a downstream antiviral cascade that includes miRNAs (Li and Shi, 2013). For instance, in hepatitis C virus (HCV)-infected hepatocytes, type I interferon (IFNα/β) production caused by endosomal TLR activation rapidly modulates the expression of numerous host miRNAs, including miR-196, miR-296, miR-351, miR-431 and miR-448, that target the HCV RNA genome with the aim to inhibit viral replication (Pedersen et al., 2007).
Virus-dependent activation of PRRs can also induce the expression of miRNAs able to promote innate immunity through a positive feedback regulatory loop. In an infection by the vesicular stomatitis virus (VSV), miR-155 and miR-223 expression is induced in macrophages through a RIG-I/JNK/NF-κB-dependent pathway. MiR-155 expression is also induced in an infection with Epstein–Barr virus (EBV) in B-cell lymphomas (Figure 1), by a mechanism involving the Activator protein 1 (AP1) transcription factor and DNA hypomethylation (Yin et al., 2016).
FIGURE 1. Viruses interfere with host miRNA biogenesis. Primary miRNAs (pri-miRNAs) processing, first to precursor miRNAs (pre-miRNAs) and then to mature miRNAs, involves two ordered endonucleolytic cleavages. Following transcription by RNA polymerase II/III, the multiprotein complex containing Drosha processes the pri-miRNA into a ∼70 nt hairpin pre-miRNA. Through the interaction with exportin-5 and Ran-GTP, the pre-miRNA is transported into the cytoplasm where it undergoes a second round of processing catalyzed by Dicer. One strand of the resulting small RNA duplex, the mature miRNA, is loaded into the RNA induced silencing complex (RISC) which post-transcriptionally regulates the expression of target genes. Expression of viral proteins termed viral suppressor of RNA silencing inhibits the loading of miRNAs into the RISC complex (tomato bushy stunt virus p19 protein) or Ago2 activity (cucumber virus 2b protein). Multiple processes mediated by Epstein–Barr virus are responsible for miR-155 upregulation, among which chromatin remodeling, cell signaling regulation and transcription factor activation. Flaviviruses sfRNA and Vaccinia virus inhibit or reduce the expression of Dicer activity, respectively. Finally, several Herpesviruses encode viral sequences complementary to mature miRNAs miR-17 and miR-27, leading to their degradation or the inhibition of the miRNA-induced regulation of mRNA targets.
In turn, both miRNAs promote the type I IFN-mediated antiviral response by suppressing cytokine signaling 1 (SOCS1) (Wang et al., 2010) and FOXO3 (Chen et al., 2016), respectively. Another example of SOCS1 suppression was observed in patient developing dengue hemorrhagic fever (DHF) and this suppression is associated with elevated levels of miR-150 in CD14+ monocytes infected with DENV2 (Chen et al., 2014).
Viral Infections Can Inhibit the Maturation of Host miRNAs Involved in the Antiviral Response
The role played by miRNAs in antiviral defenses can be counteracted by viruses that deploy specific virulence factors, referred to as viral suppressors of RNA silencing (VSRs), which target several components of the host silencing machinery including small RNA processing, stability and activity via AGO effectors (Wu et al., 2010). The 2b protein of the cucumber mosaic virus (CMV) inhibits AGO1 slicer function independently of its dsRNA-binding activity (Feng et al., 2013), while the p19 protein of the tomato bushy stunt virus (TBSV) inhibits miRISC loading activity by binding to small double-stranded (ds)RNAs (Lakatos et al., 2006). These mechanisms promote viral replication.
Flaviviruses, which are single-stranded (ss) positive-RNA viruses, interfere with the miRNA processing machinery through an accumulation of the non-coding (nc) subgenomic flavivirus RNA (sfRNAs) that induces sequestration of the dsRNA binding proteins Dicer and AGO2 (Moon et al., 2015). This viral strategy is put in place by different flaviviruses, including Murray valley encephalitis virus (MVEV), Japanese encephalitis virus (JEV), West nile virus (WNV), Yellow fever virus (YFV), and Dengue virus (DENV) (Schnettler et al., 2012; Bavia et al., 2016).
An indirect regulation of miRNA biogenesis has been observed in HeLa cells infected by vaccinia virus (VACV), a member of the Poxviridae family with a linear double-stranded DNA genome. VACV abrogates the expression of Dicer independently of VACV decapping enzymes via a mechanism that remains to be clarified (Grinberg et al., 2012) (Figure 1).
Viral Infections Can Accelerate the Degradation of Host miRNAs Involved in the Antiviral Response
Different viruses encode ncRNAs that contain sequences complementary to those of host miRNAs, thereby promoting their degradation. The γ-herpesvirus saimiri (HVS) expresses a small U-rich ncRNA, HSUR 1, which contains a sequence complementarity to miR-27 (Cazalla et al., 2010). Binding with HSUR 1 induces miR-27 degradation and this down-regulation activates T-cells during HVS infection (Guo et al., 2014). Recently, it was demonstrated that this mechanism was dependent of a flexible conformation of the miR-27 binding region on HSUR 1 (Pawlica et al., 2016). This mechanism has also been reported with the Murine cytomegalovirus (MCMV) (Libri et al., 2012; Marcinowski et al., 2012). Two other oncogenic γ-herpesviruses, alcelaphine herpesvirus 1 and ovine herpesvirus 2, encode viral homologes of miR-27 target genes leading to rapid decay of this miRNA (Guo et al., 2014).
Human cytomegalovirus (HCMV) expresses an nc-transcript, called miRNA decay element (miRDE), that contains several binding sites for miR-17 family members, the binding of which causes their degradation. This proviral function leads to an upregulation of viral DNA synthesis and viral production during lytic infection (Lee et al., 2013) (Figure 1).
These examples show that viral infections can trigger the expression of antiviral miRNAs, but can also regulate miRNA turnover and function in order to favor their own propagation. The mechanisms by which miRNAs are degraded after a viral infection need to be clarified but could involve 3′-end addition of non-templated nucleotides by tailing enzymes, followed by degradation by exonucleases (Ameres et al., 2010; Marcinowski et al., 2012; McCaskill et al., 2015).
Host miRNAs Control Viral RNA Production and Turnover
Host miRNAs have been reported to directly target viral RNAs to promote or inhibit the viral lifecycle.
Host miRNAs Can Directly Block Viral Replication
Elevated levels of miR-296-5p were detected in Enterovirus 71 (EV71)-infected human rhabdomyosarcoma (RD) and SK-N-Sh cells. MiR-296-5p targets both capsid protein VP1 and VP3 coding regions in the viral genome as a response to viral infection (Zheng et al., 2013). Other miRNAs inhibit EV71 replication, such as miR-23b that targets the EV71 VP1 RNA coding region (Ho et al., 2016).
Coxsackievirus B3 (CVB3) is an RNA virus belonging to the Picornaviridae family that provokes cardiomyopathies. In HeLa cells, miR-342-5p targets the 2C-coding region of the viral RNA, which results in its degradation (Wang et al., 2012).
Herpes simplex virus type 1 (HSV-1) replicates in epithelial cells and persists in a latent form in sensory neurons. Lytic replication and reactivation from latency depend on the expression of viral Infected Cell Protein 0 (ICP0), which is controlled by the cell-specific miR-138 in neurons (Pan et al., 2014).
Another example is provided by miR-548g-3p that targets the Stem Loop A promoter element of DENV 5′-UTR, inhibiting the recruitment of the viral RNA-dependent RNA polymerase (NS5) to the viral genome and resulting in a blockade of viral replication (Wen et al., 2015).
Host miRNAs Can Suppress Proviral Host Factors
Host miRNAs can play an antiviral role by targeting host mRNAs that encode proviral proteins. In human EAhy926 cells infected with DENV-2, miR-223 downregulates the microtubule-destabilizing protein stathmin 1 (STMN1), thereby inhibiting viral replication (Wu et al., 2014). MiR-199a-3p inhibits the replication of different viruses, including herpesviruses and alphaviruses, via downregulation of ERK/MAPK, oxidative stress and PI3K/AKT pathway activation (Santhakumar et al., 2010). The WNVKUN-induced miR-532-5p downregulates SESTD1 (SEC14 and spectrin domains 1) and TAB3 (TGF-beta activated kinase 1/MAP3K7 binding protein 3) mRNAs to block WNV replication (Slonchak et al., 2015).
Host miRNAs Can Act As Proviral Factors through Direct Interaction with the Viral Genome
Competition for miRNA binding has been reported in the case of human diseases and is termed “competitive viral and host RNAs” (cvhRNA) (Li et al., 2014). In infected cells, the interaction between viral RNAs and host miRNAs could be necessary for viral RNA stability, replication, or infection (Jopling et al., 2005). Therefore, viral RNAs harboring common miRNA-binding sites with host mRNA could act as sponges and sequester endogenous miRNAs. In fine, the stability and translational efficiency of cellular mRNA targets (“targetome”) is increased in infected cells (Figure 2). The liver-specific miR-122 is an example of such a strategy adopted by HCV (Luna et al., 2015). MiR-122 binds two sites within the 5′-UTR of the HCV RNA genome and this binding moderately stimulates viral protein translation (Henke et al., 2008) while it protects the genome from XRN1-mediated degradation (Shimakami et al., 2012; Li et al., 2013; Sedano and Sarnow, 2014). In addition, miR-122 competes with cellular poly(rC)-binding protein 2 (PCBP2) binding to the HCV RNA genome and thereby promotes replication and packaging (Masaki et al., 2015). Similarly, pestiviruses hijack miR-17 and let-7 family members to promote their replication. Indeed, both let-7s and miR-17s directly interact with the 3′-UTR of the viral genome so as to stabilize the bovine viral diarrhea virus (BVDV) RNA and increase its translation (Scheel et al., 2016). Finally, miR-10a star strand (miR-10a-3p) directly targets CVB3 3D-coding sequence, thereby favoring its replication. Further in vivo investigations are required to elucidate the role of miR-10a-3p during CVB3 infection, in which a post-transcriptional regulation seems to be involved (Tong et al., 2013).
FIGURE 2. Host miRNAs directly improve RNA virus replication. Direct interaction of 3′ end- bovine viral diarrhea virus (BVDV), 3D-coding of region Coxsackie virus B3 (CVB3), and 5′-IRES of hepatitis C virus (HCV) RNAs with host miR-17, let-7, miR-10a-3p, and miR-122, respectively, increases viral replication (dark arrows). The unusual interaction between host miRNA and increasing amounts of viral RNA during replication implies a diminution of the interaction of the host miRNA with its cellular targets (“sponge effect”) (dark dotted inhibition arrows). MiR-10a-3p targets mRNAs implicated in temozolomide resistance (Ujifuku et al., 2010) indicating that miR-10a-3p is not only a passenger miRNA but has a functional role in the cells [image source for CVB3 (Luo et al., 2010) and HCV (Lindenbach and Rice, 2013)].
Host miRNAs Can Act As Proviral Factors by Inhibiting Antiviral Host Factors
In DENV and VSV-infected monocytes/macrophages, and in JEV (strain JaOArS982) -infected human microglial brain cells (CHME3), the induction of miR-146a expression suppresses type I IFN production by targeting IL-1 receptor-associated kinase 1 (IRAK1), IRAK2, and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), thereby enhancing viral replication or allowing viral escape to cellular immune response (Hou et al., 2009; Wu et al., 2013; Zhang and Li, 2013; Sharma et al., 2015) (Figure 3). EV71 infection in RD cells also led to elevated levels of miR-146a. In this model, AP1 is the key transcription factor involved and miR-146a suppresses IRAK1 and TRAF6 expression leading to the inhibition of IFN production, and viral evasion to host immune attacks (Ho et al., 2014). White spot syndrome virus (WSSV) infection induces the up-regulation of miR-9041 and miR-9850, which in turn inhibit the JAK/STAT pathway, an inhibition resulting in the reduced expression of interferon-induced genes (Huang et al., 2016). HCV-dependent upregulation of miR-373 in hepatocytes is another example of a viral-induced inhibition of the JAK/STAT pathway, through targeting JAK1 and IFN-regulating factor 9 (IRF9) mRNAs (Mukherjee et al., 2015). Finally, type I interferon production is downregulated by non-structural proteins 1 and 2 (NS1 and NS2) encoded by RSV genome through the induction of miR-29a, which targets the IFN-alpha receptor (IFNAR1) 3′-UTR (Zhang et al., 2016) (Figure 4).
FIGURE 3. Host miRNA-146a favors viral replication. MiR-146a expression is increased upon vesicular stomatitis virus (VSV), Japanese encephalitis virus (JEV), and Dengue virus infection. In the case of VSV infection, miR-146a expression is increased in a RIG-I dependent manner. The RIG-I protein interacts with VSV RNA via its helicase domain, leading to the nuclear transcription of pri-miR-146a by NF-kB, and to an increasing amount of miR-146a. The proviral function of miR-146a is explained by the diminution of target mRNAs such as IRAK1, IRAK2, which are essential partners of the type I interferon response [image source for JEV adapted from Luca et al. (2012)].
FIGURE 4. Host miRNAs that favor viral replication via the inhibition of the Jak/STAT signaling pathway. Cellular miRNAs (miR-9041, miR-9850, miR-29a, and miR-373) are upregulated during DNA [White spot syndrome virus (WSSV)] or RNA (respiratory syncytial virus, HCV) viruses infections. The proviral function of miR-9041, miR-9850, miR-29a, and miR-373 is explained by the diminution of target mRNAs coding for key elements of the JAK/STAT signaling pathway, such as STAT, IFNAR, JAK1, IRF9. Consequently, the formation of the STAT-IRF9 complex is impaired and the activity of the ISRE (interferon-stimulated response element) promoter is reduced (dotted arrows) [image source for HCV (Lindenbach and Rice, 2013)].
Altogether, host miRNAs influence the fate of viral infections, by inducing antiviral responses, by modulating cellular tropism or by playing a facilitating role in various phases of the viral life-cycles. However, because cellular miRNAs control multiple processes, their hijacking by viruses leads to the derepression of various cellular mRNAs, causing aberrant host protein expression. The most likely hypothesis is that viral adaptation was the result of host miRNA–mRNA interaction alterations, making the host cell environment favorable to viral persistence/chronicity (Li et al., 2014).
Viral miRNAs (v-miRNAs)
Besides host miRNAs and the various roles they play in the virus–host interaction and resulting infection, certain viruses have been shown to generate their own miRNAs, which play a role in the viral life-cycles and may induce metabolic perturbations in the infected cells (Table 1).
TABLE 1. Viruses, v-miRNAs and their functions.
v-miRNA Biogenesis
DNA Virus v-miRNAs
Since the discovery of the expression of miRNA by DNA viruses (Pfeffer et al., 2004), many research investigations have been conducted to identify and unravel the roles of these v-miRNAs. The functions described so far encompass regulation of viral persistence, proliferation and long-term survival of host cell and host immune evasion (Tycowski et al., 2015). Like eukaryotic miRNAs, v-miRNAs are generally processed by DROSHA and Dicer. In some cases, such as adenoviruses, pre-v-miRNAs can be directly transcribed and processed by Dicer, skipping the DROSHA step (Aparicio et al., 2006; Tycowski et al., 2015).
In HVS infection, which causes T-cell leukemias and lymphomas in new world primates, three pre-v-miRNAs are encoded immediately downstream of three Herpesvirus saimiri U snRNAs (HSURs 2, 4, and 5), forming chimeric HSV pri-snRNA/v-miRNAs. These chimeric transcripts are then processed by the Integrator host complex into pre-miRNAs from the 3′-end and Herpesvirus saimiri U snRNAs (HSURs) from the 5′-end extremities (Cazalla et al., 2011). These v-miRNAs, which do not bind to the HVS genome, repress many host mRNAs, preferentially those encoding cell cycle regulators (Guo et al., 2015).
Another class of DROSHA-independent miRNAs includes the Murine Gammaherpesvirus 68 (MHV68) v-miRNAs which are essential for transition to latency in the key virus reservoir of memory B-cells and for pathogenesis (Feldman et al., 2014). These v-miRNAs are transcribed as chimeric pri-RNAs consisting of tRNAs linked to pre-microRNA hairpins. Host tRNaseZ cleavage removes the tRNA and frees the pre-microRNA for Dicer processing (Bogerd et al., 2010; Diebel et al., 2010).
Cytoplasmic RNA Virus v-miRNAs
Although this is debated, it appears that some cytoplasmic RNA viruses could generate v-miRNAs (Swaminathan et al., 2013). The WNV Kunjin strain contains a sfRNAs in the 3′-UTR of its genomic RNA with several stem–loops that serve as Dicer substrates for the generation of v-miRNAs called KUN-miR-1. These v-miRNAs enhance viral replication (Hussain et al., 2012).
The discovery that cytoplasmic RNA viruses could be engineered to produce functional miRNAs emphasizes the existence of cytoplasmic, non-canonical, miRNA biogenesis pathways. For instance, infection of BHK cells by cytoplasmic recombinant Sindbis viruses (rSINVs) allows the expression of virus-derived cytoplasmic pri-miRNAs (c-pri-miRNAs). The viral-induced translocation of DROSHA into the cytoplasm initiates the processing of these c-pri-miRNAs and the biogenesis of miRNAs (Shapiro et al., 2012).
Retrovirus v-miRNAs
Retroviruses constitute a class of positive-sense ssRNA viruses, ubiquitous in nature, causing cancers and immunodeficiency syndromes, which are reverse transcribed to dsDNAs that integrates the host genome (Zheng et al., 2012). The capacity of Human immunodeficiency virus 1 (HIV-1) to encode v-miRNAs has been extensively studied both in silico and in vivo (Bennasser et al., 2004). HIV1-miR-H1 is generated from a pre-miRNA sequence within the 3′-end of the viral genome. In human mononuclear cells, this v-miRNA has been reported to selectively target the apoptosis antagonizing transcription factor (AATF) transcript, thereby suppressing the expression of c-myc, Par-4, Bcl-2 and the RISC protein Dicer. This v-miRNA also downregulates the host miR-149, which targets the viral accessory protein Vpr (Kaul et al., 2009). A 50 nt HIV-1 TAR motif located within the 5′ end of the viral genome is also a source of several v-miRNAs (Narayanan et al., 2011). Other retroviruses than HIV generate v-miRNAs using either canonical or non-canonical miRNA biogenesis pathways. They include the avian leukosis virus (Lakatos et al., 2006; Yao et al., 2014), the bovine leukemia virus (BLV), the bovine foamy virus (BFV) (Kincaid et al., 2012; Burke et al., 2014; Whisnant et al., 2014), and the simian foamy virus (SFV) (Tycowski et al., 2015).
v-miRNAs Functions
Regulation of Viral Life-Cycles
Several v-miRNAs are generated from the antisense strand of viral protein-coding genes, showing a perfect match to their target mRNAs. In general, these antisense v-miRNAs are involved in the lytic or latency phase transition (Grassmann and Jeang, 2008). For instance, EBV expresses the BamHI-A antisense transcripts (BARTs) that produces v-miRNAs. The EBV BARTs produce two clusters of miRNAs (12 and 15 v-miRNAs in Clusters 1 and 2, respectively). It was reported that BART cluster 1 miRNAs target the viral LMP-1 3′-UTR, a prime candidate for driving nasopharyngeal carcinoma (NPC) development. Negative regulation of LMP1 expression may thus favor EBV-associated cancer development (Lo et al., 2007). Moreover, BART20-derived v-miRNA promotes the latency phase by targeting two EBV immediate-early genes, including BZLF1 and BRLF1 (Jung et al., 2014).
Human cytomegalovirus lytic replication is regulated by miR-UL112-1 that targets the IE1 (immediate early viral protein) 3′-UTR, thereby sustaining the latency phase (Grassmann and Jeang, 2008). Likewise, the ovine herpesvirus v-miRNA, OvHV-2-miR-5, targets ORF50 mRNA and maintains latency (Riaz et al., 2014). A v-miRNA-dependent strategy is also employed by HSV-1, which encodes miR-H2-3p that directly targets latency-associated transcripts, including the viral immediate early gene transactivator (Umbach et al., 2008).
Host mRNA Regulation
Viral-miRNAs can also regulate the expression of host mRNAs. v-miRNAs from KSHV target different host mRNAs, including the IκBα mRNA, activating NF-κB signaling and preventing viral lytic replication (Lei et al., 2010). Similarly, the EBV specific BART18-derived v-miRNA targets the MAPK kinase kinase 2 mRNA, thereby preventing the initiation of lytic viral replication (Qiu and Thorley-Lawson, 2014). Other EBV- or KSHV-expressed v-miRNAs reduce the expression of pro-apoptotic proteins or inhibit cell cycle progression (Gottwein and Cullen, 2010). Notably, v-miRNAs from some gamma-herpesviruses, such as KSHV and Marek’s disease virus type 1 (MDV-1), or retroviruses, such as SFV, share the same seed-sequence of miR-155 and regulate the miR-155 targetome (Guo and Steitz, 2014).
Several v-miRNAs enhance viral survival by targeting genes involved in the antiviral immune response. For example, the KSHV-expressed miR-K12-10a directly reduces the expression of TWEAKR (TNF-like weak inducer of apoptosis receptor) (Abend et al., 2010), whereas miR-K12-9 and miR-K12-5 target the TLR/Interleukin-1R signaling cascade at two distinct points (IRAK1 and MYD88), thereby reducing inflammatory cytokine mRNAs expression (Abend et al., 2012). The KSHV-expressed miR-K12-11 and miR-K12-5 prevent the recognition of infected cells by natural killer (NK) cells by directly targeting the activation-induced cytidine deaminase (AID) coding gene (Bekerman et al., 2013). Similarly, HCMV-expressed v-miRNAs favors the evasion from the NK antiviral response (Nachmani et al., 2009). The HCMV v-miR-US4-1 alters the MHC class I presentation pathway by targeting endoplasmic reticulum-resident aminopeptidases, such as ERAP1, a “molecular ruler” for antigenic peptide production in T-lymphocytes (Kim et al., 2011). Moreover, HCMV-expressed miR-UL112-1, miR-US5-1, and miR-US5-2 control mRNAs encoding IL6 and TNF-α, which are involved in the secretory pathways, thereby altering the secretion of host cytokines and ultimately blocking the antiviral response (Hook et al., 2014).
These observations indicate that viruses, including DNA viruses, cytoplasmic RNA viruses and retroviruses, produce v-miRNAs through or independently of the DROSHA-dependent maturation pathways. These v-miRNAs generally play a proviral role by enhancing the viral life-cycles, impairing the expression of genes involved in antiviral responses or regulating cell metabolism (Table 1). Thus, specific v-miRNAs could represent an interesting target for antiviral interventions.
Therapeutic Manipulation of miRNAs for Antiviral Therapy
Recent advances in the field of antiviral therapy consist of specifically inhibiting a viral component in order to block the viral life-cycle, and thereby inhibiting viral production. The roles played by several host miRNAs and by v-miRNAs pave the way to specific antagomirs approaches. Such an approach has been applied to HCV in several in vitro and in vivo proof-of-concept studies. A specific inhibitor (antagomir) of miR-122 [miravirsen, Santaris Pharma, Hørsholm, Denmark] entered into human clinical trials (Janssen et al., 2013). In a phase II trial, 5 weekly miravirsen injections induced a dose-dependent reduction of HCV RNA levels ranging from 1.2 to 3.0 Log international units (IUs)/mL, which was maintained after treatment cessation. Five out of 27 patients still had undetectable HCV RNA 14 weeks after the end of therapy. In a recent trial (van der Ree et al., 2017), RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonizes miR-122, inhibited viral replication by up to 5 Log IU/mL after one single injection of the antagomir, and 3 out of 32 patients were even cured of the infection. These very promising results suggest that antagomir-based approaches are susceptible to profoundly and sustainably inhibit viral replication.
Currently, a major barrier to the application of miRNA/siRNA-based therapies is the non-toxic delivery to infected sites (Tahamtan et al., 2016). Delivery of sufficient amounts of miRNA/anti-miRNA molecules is indeed challenging. Host miRNAs are key regulators of gene expression, and their long-term manipulation may predispose one to cellular abnormalities, impaired immunity, or even cell transformation. Therefore, side-effects correlated with long-term suppression/overexpression of host miRNAs may limit the clinical use of such strategies. Targeting v-miRNAs rather than host miRNAs could be a reasonable alternative in some cases. More preclinical and early clinical studies are now warranted.
Conclusion and Perspectives
In summary, we are far from fully understanding the molecular mechanisms underlying the complex crosstalks between miRNA pathways and viral infections. Deciphering the pathways of v-miRNAs generation, for DNA or RNA viruses, remains challenging as well. However, knowledge is increasing on the diverse roles played by either host miRNAs or v-miRNAs during viral infections. It is now necessary to decipher virus/miRNA networks and unravel the detailed miRNA/v-miRNA mechanism(s) during viral infections and the antiviral response, in order to improve our antiviral armamentarium to cure or control a number of viral infections without current therapies.
Author Contributions
All authors contributed to the planning, writing, and revision of the manuscript. All authors read and approved the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This study was supported by the Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS #ECTZ24969) to CF and MT. We thank A. Reid for critical reading of the manuscript.
References
Abdelmohsen, K., Srikantan, S., Kang, M. J., and Gorospe, M. (2012). Regulation of senescence by microRNA biogenesis factors. Ageing Res. Rev. 11, 491–500. doi: 10.1016/j.arr.2012.01.003
Abend, J. R., Ramalingam, D., Kieffer-Kwon, P., Uldrick, T. S., Yarchoan, R., and Ziegelbauer, J. M. (2012). Kaposi’s sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J. Virol. 86, 11663–11674. doi: 10.1128/JVI.01147-12
Abend, J. R., Uldrick, T., and Ziegelbauer, J. M. (2010). Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi’s sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression. J. Virol. 84, 12139–12151. doi: 10.1128/JVI.00884-10
Ameres, S. L., Horwich, M. D., Hung, J. H., Xu, J., Ghildiyal, M., Weng, Z., et al. (2010). Target RNA-directed trimming and tailing of small silencing RNAs. Science 328, 1534–1539. doi: 10.1126/science.1187058
Aparicio, O., Razquin, N., Zaratiegui, M., Narvaiza, I., and Fortes, P. (2006). Adenovirus virus-associated RNA is processed to functional interfering RNAs involved in virus production. J. Virol. 80, 1376–1384. doi: 10.1128/JVI.80.3.1376-1384.2006
Bavia, L., Mosimann, A. L., Aoki, M. N., and Duarte Dos Santos, C. N. (2016). A glance at subgenomic flavivirus RNAs and microRNAs in flavivirus infections. Virol. J. 13, 84. doi: 10.1186/s12985-016-0541-3
Bekerman, E., Jeon, D., Ardolino, M., and Coscoy, L. (2013). A role for host activation-induced cytidine deaminase in innate immune defense against KSHV. PLoS Pathog. 9:e1003748. doi: 10.1371/journal.ppat.1003748
Bennasser, Y., Le, S. Y., Yeung, M. L., and Jeang, K. T. (2004). HIV-1 encoded candidate micro-RNAs and their cellular targets. Retrovirology 1, 43. doi: 10.1186/1742-4690-1-43
Bogerd, H. P., Karnowski, H. W., Cai, X., Shin, J., Pohlers, M., and Cullen, B. R. (2010). A mammalian herpesvirus uses noncanonical expression and processing mechanisms to generate viral MicroRNAs. Mol. Cell 37, 135–142. doi: 10.1016/j.molcel.2009.12.016
Brennecke, J., Stark, A., Russell, R. B., and Cohen, S. M. (2005). Principles of microRNA-target recognition. PLoS Biol. 3:e85. doi: 10.1371/journal.pbio.0030085
Burke, J. M., Bass, C. R., Kincaid, R. P., and Sullivan, C. S. (2014). Identification of tri-phosphatase activity in the biogenesis of retroviral microRNAs and RNAP III-generated shRNAs. Nucleic Acids Res. 42, 13949–13962. doi: 10.1093/nar/gku1247
Cazalla, D., Xie, M., and Steitz, J. A. (2011). A primate herpesvirus uses the integrator complex to generate viral microRNAs. Mol. Cell 43, 982–992. doi: 10.1016/j.molcel.2011.07.025
Cazalla, D., Yario, T., and Steitz, J. A. (2010). Down-regulation of a host microRNA by a Herpesvirus saimiri noncoding RNA. Science 328, 1563–1566. doi: 10.1126/science.1187197
Chen, L., Song, Y., He, L., Wan, X., Lai, L., Dai, F., et al. (2016). MicroRNA-223 Promotes Type I interferon production in antiviral innate immunity by targeting forkhead box protein O3 (FOXO3). J. Biol. Chem. 291, 14706–14716. doi: 10.1074/jbc.M115.700252
Chen, R. F., Yang, K. D., Lee, I. K., Liu, J. W., Huang, C. H., Lin, C. Y., et al. (2014). Augmented miR-150 expression associated with depressed SOCS1 expression involved in dengue hemorrhagic fever. J. Infect. 69, 366–374. doi: 10.1016/j.jinf.2014.05.013
Chi, S. W., Hannon, G. J., and Darnell, R. B. (2012). An alternative mode of microRNA target recognition. Nat. Struct. Mol. Biol. 19, 321–327. doi: 10.1038/nsmb.2230
Diebel, K. W., Smith, A. L., and van Dyk, L. F. (2010). Mature and functional viral miRNAs transcribed from novel RNA polymerase III promoters. RNA 16, 170–185. doi: 10.1261/rna.1873910
Emde, A., Eitan, C., Liou, L. L., Libby, R. T., Rivkin, N., Magen, I., et al. (2015). Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J. 34, 2633–2651. doi: 10.15252/embj.201490493
Feldman, E. R., Kara, M., Coleman, C. B., Grau, K. R., Oko, L. M., Krueger, B. J., et al. (2014). Virus-encoded microRNAs facilitate gammaherpesvirus latency and pathogenesis in vivo. MBio 5, e00981–14. doi: 10.1128/mBio.00981-14
Feng, L., Duan, C. G., and Guo, H. S. (2013). Inhibition of in vivo Slicer activity of Argonaute protein 1 by the viral 2b protein independent of its dsRNA-binding function. Mol. Plant Pathol. 14, 617–622. doi: 10.1111/mpp.12033
Frezzetti, D., Reale, C., Cali, G., Nitsch, L., Fagman, H., Nilsson, O., et al. (2011). The microRNA-processing enzyme Dicer is essential for thyroid function. PLoS ONE 6:e27648. doi: 10.1371/journal.pone.0027648
Friedman, R. C., Farh, K. K., Burge, C. B., and Bartel, D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105. doi: 10.1101/gr.082701.108
Ghildiyal, M., and Zamore, P. D. (2009). Small silencing RNAs: an expanding universe. Nat. Rev. Genet. 10, 94–108. doi: 10.1038/nrg2504
Gottwein, E., and Cullen, B. R. (2010). A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. J. Virol. 84, 5229–5237. doi: 10.1128/JVI.00202-10
Grassmann, R., and Jeang, K. T. (2008). The roles of microRNAs in mammalian virus infection. Biochim. Biophys. Acta 1779, 706–711. doi: 10.1016/j.bbagrm.2008.05.005
Gregory, R. I., Chendrimada, T. P., and Shiekhattar, R. (2006). MicroRNA biogenesis: isolation and characterization of the microprocessor complex. Methods Mol. Biol. 342, 33–47. doi: 10.1385/1-59745-123-1:33
Grinberg, M., Gilad, S., Meiri, E., Levy, A., Isakov, O., Ronen, R., et al. (2012). Vaccinia virus infection suppresses the cell microRNA machinery. Arch. Virol. 157, 1719–1727. doi: 10.1007/s00705-012-1366-z
Guil, S., and Caceres, J. F. (2007). The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat. Struct. Mol. Biol. 14, 591–596. doi: 10.1038/nsmb1250
Guo, Y. E., Oei, T., and Steitz, J. A. (2015). Herpesvirus saimiri MicroRNAs preferentially target host cell cycle regulators. J. Virol. 89, 10901–10911. doi: 10.1128/JVI.01884-15
Guo, Y. E., Riley, K. J., Iwasaki, A., and Steitz, J. A. (2014). Alternative capture of noncoding RNAs or protein-coding genes by herpesviruses to alter host T cell function. Mol. Cell 54, 67–79. doi: 10.1016/j.molcel.2014.03.025
Guo, Y. E., and Steitz, J. A. (2014). Virus meets host microRNA: the destroyer, the booster, the hijacker. Mol. Cell. Biol. 34, 3780–3787. doi: 10.1128/MCB.00871-14
Ha, M., and Kim, V. N. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509–524. doi: 10.1038/nrm3838
Hata, A., and Lieberman, J. (2015). Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci. Signal. 8, re3. doi: 10.1126/scisignal.2005825
Helwak, A., Kudla, G., Dudnakova, T., and Tollervey, D. (2013). Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153, 654–665. doi: 10.1016/j.cell.2013.03.043
Henke, J. I., Goergen, D., Zheng, J., Song, Y., Schuttler, C. G., Fehr, C., et al. (2008). microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27, 3300–3310. doi: 10.1038/emboj.2008.244
Ho, B. C., Yang, P. C., and Yu, S. L. (2016). MicroRNA and pathogenesis of enterovirus infection. Viruses 8:E11. doi: 10.3390/v8010011
Ho, B. C., Yu, I. S., Lu, L. F., Rudensky, A., Chen, H. Y., Tsai, C. W., et al. (2014). Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon. Nat. Commun. 5:3344. doi: 10.1038/ncomms4344
Hook, L. M., Grey, F., Grabski, R., Tirabassi, R., Doyle, T., Hancock, M., et al. (2014). Cytomegalovirus miRNAs target secretory pathway genes to facilitate formation of the virion assembly compartment and reduce cytokine secretion. Cell Host Microbe 15, 363–373. doi: 10.1016/j.chom.2014.02.004
Hou, J., Wang, P., Lin, L., Liu, X., Ma, F., An, H., et al. (2009). MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 183, 2150–2158. doi: 10.4049/jimmunol.0900707
Huang, Y., Wang, W., and Ren, Q. (2016). Two host microRNAs influence WSSV replication via STAT gene regulation. Sci. Rep. 6:23643. doi: 10.1038/srep23643
Hussain, M., Torres, S., Schnettler, E., Funk, A., Grundhoff, A., Pijlman, G. P., et al. (2012). West Nile virus encodes a microRNA-like small RNA in the 3′ untranslated region which up-regulates GATA4 mRNA and facilitates virus replication in mosquito cells. Nucleic Acids Res. 40, 2210–2223. doi: 10.1093/nar/gkr848
Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., et al. (2013). Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685–1694. doi: 10.1056/NEJMoa1209026
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., and Sarnow, P. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577–1581. doi: 10.1126/science.1113329
Jung, Y. J., Choi, H., Kim, H., and Lee, S. K. (2014). MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1. J. Virol. 88, 9027–9037. doi: 10.1128/JVI.00721-14
Kaul, D., Ahlawat, A., and Gupta, S. D. (2009). HIV-1 genome-encoded hiv1-mir-H1 impairs cellular responses to infection. Mol. Cell. Biochem. 323, 143–148. doi: 10.1007/s11010-008-9973-4
Kim, S., Lee, S., Shin, J., Kim, Y., Evnouchidou, I., Kim, D., et al. (2011). Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat. Immunol. 12, 984–991. doi: 10.1038/ni.2097
Kim, V. N., Han, J., and Siomi, M. C. (2009). Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10, 126–139. doi: 10.1038/nrm2632
Kincaid, R. P., Burke, J. M., and Sullivan, C. S. (2012). RNA virus microRNA that mimics a B-cell oncomiR. Proc. Natl. Acad. Sci. U.S.A. 109, 3077–3082. doi: 10.1073/pnas.1116107109
Kulkarni, M., Ozgur, S., and Stoecklin, G. (2010). On track with P-bodies. Biochem. Soc. Trans. 38(Pt 1), 242–251. doi: 10.1042/BST0380242
Lakatos, L., Csorba, T., Pantaleo, V., Chapman, E. J., Carrington, J. C., Liu, Y. P., et al. (2006). Small RNA binding is a common strategy to suppress RNA silencing by several viral suppressors. EMBO J. 25, 2768–2780. doi: 10.1038/sj.emboj.7601164
Lee, S., Song, J., Kim, S., Kim, J., Hong, Y., Kim, Y., et al. (2013). Selective degradation of host MicroRNAs by an intergenic HCMV noncoding RNA accelerates virus production. Cell Host Microbe 13, 678–690. doi: 10.1016/j.chom.2013.05.007
Lee, Y., Kim, M., Han, J., Yeom, K. H., Lee, S., Baek, S. H., et al. (2004). MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051–4060. doi: 10.1038/sj.emboj.7600385
Lei, X., Bai, Z., Ye, F., Xie, J., Kim, C. G., Huang, Y., et al. (2010). Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat. Cell Biol. 12, 193–199. doi: 10.1038/ncb2019
Lewis, B. P., Burge, C. B., and Bartel, D. P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20. doi: 10.1016/j.cell.2004.12.035
Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P., and Burge, C. B. (2003). Prediction of mammalian microRNA targets. Cell 115, 787–798. doi: 10.1016/S0092-8674(03)01018-3
Li, C., Hu, J., Hao, J., Zhao, B., Wu, B., Sun, L., et al. (2014). Competitive virus and host RNAs: the interplay of a hidden virus and host interaction. Protein Cell 5, 348–356. doi: 10.1007/s13238-014-0039-y
Li, Y., Masaki, T., Yamane, D., McGivern, D. R., and Lemon, S. M. (2013). Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc. Natl. Acad. Sci. U.S.A. 110, 1881–1886. doi: 10.1073/pnas.1213515110
Li, Y., and Shi, X. (2013). MicroRNAs in the regulation of TLR and RIG-I pathways. Cell. Mol. Immunol. 10, 65–71. doi: 10.1038/cmi.2012.55
Libri, V., Helwak, A., Miesen, P., Santhakumar, D., Borger, J. G., Kudla, G., et al. (2012). Murine cytomegalovirus encodes a miR-27 inhibitor disguised as a target. Proc. Natl. Acad. Sci. U.S.A. 109, 279–284. doi: 10.1073/pnas.1114204109
Lindenbach, B. D., and Rice, C. M. (2013). The ins and outs of hepatitis C virus entry and assembly. Nat. Rev. Microbiol. 11, 688–700. doi: 10.1038/nrmicro3098
Lo, A. K., To, K. F., Lo, K. W., Lung, R. W., Hui, J. W., Liao, G., et al. (2007). Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl. Acad. Sci. U.S.A. 104, 16164–16169. doi: 10.1073/pnas.0702896104
Luca, V. C., AbiMansour, J., Nelson, C. A., and Fremont, D. H. (2012). Crystal structure of the Japanese encephalitis virus envelope protein. J. Virol. 86, 2337–2346. doi: 10.1128/JVI.06072-11
Luna, J. M., Scheel, T. K., Danino, T., Shaw, K. S., Mele, A., Fak, J. J., et al. (2015). Hepatitis C virus RNA functionally sequesters miR-122. Cell 160, 1099–1110. doi: 10.1016/j.cell.2015.02.025
Luo, H., Wong, J., and Wong, B. (2010). Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy. Cardiovasc. Res. 85, 347–356. doi: 10.1093/cvr/cvp225
Marcinowski, L., Tanguy, M., Krmpotic, A., Radle, B., Lisnic, V. J., Tuddenham, L., et al. (2012). Degradation of cellular mir-27 by a novel, highly abundant viral transcript is important for efficient virus replication in vivo. PLoS Pathog. 8:e1002510. doi: 10.1371/journal.ppat.1002510
Masaki, T., Arend, K. C., Li, Y., Yamane, D., McGivern, D. R., Kato, T., et al. (2015). miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation. Cell Host Microbe 17, 217–228. doi: 10.1016/j.chom.2014.12.014
McCaskill, J., Praihirunkit, P., Sharp, P. M., and Buck, A. H. (2015). RNA-mediated degradation of microRNAs: a widespread viral strategy? RNA Biol. 12, 579–585. doi: 10.1080/15476286.2015.1034912
Moon, S. L., Dodd, B. J., Brackney, D. E., Wilusz, C. J., Ebel, G. D., and Wilusz, J. (2015). Flavivirus sfRNA suppresses antiviral RNA interference in cultured cells and mosquitoes and directly interacts with the RNAi machinery. Virology 485, 322–329. doi: 10.1016/j.virol.2015.08.009
Mukherjee, A., Di Bisceglie, A. M., and Ray, R. B. (2015). Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway. J. Virol. 89, 3356–3365. doi: 10.1128/JVI.03085-14
Nachmani, D., Stern-Ginossar, N., Sarid, R., and Mandelboim, O. (2009). Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5, 376–385. doi: 10.1016/j.chom.2009.03.003
Narayanan, A., Kehn-Hall, K., Bailey, C., and Kashanchi, F. (2011). Analysis of the roles of HIV-derived microRNAs. Expert Opin. Biol. Ther. 11, 17–29. doi: 10.1517/14712598.2011.540564
Pan, D., Flores, O., Umbach, J. L., Pesola, J. M., Bentley, P., Rosato, P. C., et al. (2014). A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and promotes latency. Cell Host Microbe 15, 446–456. doi: 10.1016/j.chom.2014.03.004
Pasquinelli, A. E. (2012). MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 13, 271–282. doi: 10.1038/nrg3162
Pawlica, P., Moss, W. N., and Steitz, J. A. (2016). Host miRNA degradation by Herpesvirus saimiri small nuclear RNA requires an unstructured interacting region. RNA 22, 1181–1189. doi: 10.1261/rna.054817.115
Pedersen, I. M., Cheng, G., Wieland, S., Volinia, S., Croce, C. M., Chisari, F. V., et al. (2007). Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449, 919–922. doi: 10.1038/nature06205
Pfeffer, S., Zavolan, M., Grasser, F. A., Chien, M., Russo, J. J., Ju, J., et al. (2004). Identification of virus-encoded microRNAs. Science 304, 734–736. doi: 10.1126/science.1096781
Qiu, J., and Thorley-Lawson, D. A. (2014). EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells. Proc. Natl. Acad. Sci. U.S.A. 111, 11157–11162. doi: 10.1073/pnas.1406136111
Repetto, E., Briata, P., Kuziner, N., Harfe, B. D., McManus, M. T., Gherzi, R., et al. (2012). Let-7b/c enhance the stability of a tissue-specific mRNA during mammalian organogenesis as part of a feedback loop involving KSRP. PLoS Genet. 8:e1002823. doi: 10.1371/journal.pgen.1002823
Riaz, A., Dry, I., Levy, C. S., Hopkins, J., Grey, F., Shaw, D. J., et al. (2014). Ovine herpesvirus-2-encoded microRNAs target virus genes involved in virus latency. J. Gen. Virol. 95(Pt 2), 472–480. doi: 10.1099/vir.0.059303-0
Santhakumar, D., Forster, T., Laqtom, N. N., Fragkoudis, R., Dickinson, P., Abreu-Goodger, C., et al. (2010). Combined agonist-antagonist genome-wide functional screening identifies broadly active antiviral microRNAs. Proc. Natl. Acad. Sci. U.S.A. 107, 13830–13835. doi: 10.1073/pnas.1008861107
Sayed, D., and Abdellatif, M. (2011). MicroRNAs in development and disease. Physiol. Rev. 91, 827–887. doi: 10.1152/physrev.00006.2010
Scheel, T. K., Luna, J. M., Liniger, M., Nishiuchi, E., Rozen-Gagnon, K., Shlomai, A., et al. (2016). A Broad RNA virus survey reveals both miRNA dependence and functional sequestration. Cell Host Microbe 19, 409–423. doi: 10.1016/j.chom.2016.02.007
Schnettler, E., Sterken, M. G., Leung, J. Y., Metz, S. W., Geertsema, C., Goldbach, R. W., et al. (2012). Noncoding flavivirus RNA displays RNA interference suppressor activity in insect and Mammalian cells. J. Virol. 86, 13486–13500. doi: 10.1128/JVI.01104-12
Sedano, C. D., and Sarnow, P. (2014). Hepatitis C virus subverts liver-specific miR-122 to protect the viral genome from exoribonuclease Xrn2. Cell Host Microbe 16, 257–264. doi: 10.1016/j.chom.2014.07.006
Shapiro, J. S., Langlois, R. A., Pham, A. M., and Tenoever, B. R. (2012). Evidence for a cytoplasmic microprocessor of pri-miRNAs. RNA 18, 1338–1346. doi: 10.1261/rna.032268.112
Sharma, N., Verma, R., Kumawat, K. L., Basu, A., and Singh, S. K. (2015). miR-146a suppresses cellular immune response during Japanese encephalitis virus JaOArS982 strain infection in human microglial cells. J. Neuroinflammation 12, 30. doi: 10.1186/s12974-015-0249-0
Shimakami, T., Yamane, D., Jangra, R. K., Kempf, B. J., Spaniel, C., Barton, D. J., et al. (2012). Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc. Natl. Acad. Sci. U.S.A. 109, 941–946. doi: 10.1073/pnas.1112263109
Slonchak, A., Shannon, R. P., Pali, G., and Khromykh, A. A. (2015). Human MicroRNA miR-532-5p exhibits antiviral activity against west nile virus via suppression of host genes SESTD1 and TAB3 required for virus replication. J. Virol. 90, 2388–2402. doi: 10.1128/JVI.02608-15
Suzuki, H. I., Arase, M., Matsuyama, H., Choi, Y. L., Ueno, T., Mano, H., et al. (2011). MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol. Cell 44, 424–436. doi: 10.1016/j.molcel.2011.09.012
Swaminathan, G., Martin-Garcia, J., and Navas-Martin, S. (2013). RNA viruses and microRNAs: challenging discoveries for the 21st century. Physiol Genomics 45, 1035–1048. doi: 10.1152/physiolgenomics.00112.2013
Tahamtan, A., Inchley, C. S., Marzban, M., Tavakoli-Yaraki, M., Teymoori-Rad, M., Nakstad, B., et al. (2016). The role of microRNAs in respiratory viral infection: friend or foe? Rev. Med. Virol. 26, 389–407. doi: 10.1002/rmv.1894
Tong, L., Lin, L., Wu, S., Guo, Z., Wang, T., Qin, Y., et al. (2013). MiR-10a∗ up-regulates coxsackievirus B3 biosynthesis by targeting the 3D-coding sequence. Nucleic Acids Res. 41, 3760–3771. doi: 10.1093/nar/gkt058
Trabucchi, M., Briata, P., Garcia-Mayoral, M., Haase, A. D., Filipowicz, W., Ramos, A., et al. (2009). The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 459, 1010–1014. doi: 10.1038/nature08025
Tycowski, K. T., Guo, Y. E., Lee, N., Moss, W. N., Vallery, T. K., Xie, M., et al. (2015). Viral noncoding RNAs: more surprises. Genes Dev. 29, 567–584. doi: 10.1101/gad.259077.115
Ujifuku, K., Mitsutake, N., Takakura, S., Matsuse, M., Saenko, V., Suzuki, K., et al. (2010). miR-195, miR-455-3p and miR-10a∗ are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 296, 241–248. doi: 10.1016/j.canlet.2010.04.013
Umbach, J. L., Kramer, M. F., Jurak, I., Karnowski, H. W., Coen, D. M., and Cullen, B. R. (2008). MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 454, 780–783. doi: 10.1038/nature07103
van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., et al. (2017). Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet 389, 709–717. doi: 10.1016/S0140-6736(16)31715-9
Wang, L., Qin, Y., Tong, L., Wu, S., Wang, Q., Jiao, Q., et al. (2012). MiR-342-5p suppresses coxsackievirus B3 biosynthesis by targeting the 2C-coding region. Antiviral Res. 93, 270–279. doi: 10.1016/j.antiviral.2011.12.004
Wang, P., Hou, J., Lin, L., Wang, C., Liu, X., Li, D., et al. (2010). Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J. Immunol. 185, 6226–6233. doi: 10.4049/jimmunol.1000491
Wen, W., He, Z., Jing, Q., Hu, Y., Lin, C., Zhou, R., et al. (2015). Cellular microRNA-miR-548g-3p modulates the replication of dengue virus. J. Infect. 70, 631–640. doi: 10.1016/j.jinf.2014.12.001
Whisnant, A. W., Kehl, T., Bao, Q., Materniak, M., Kuzmak, J., Lochelt, M., et al. (2014). Identification of novel, highly expressed retroviral microRNAs in cells infected by bovine foamy virus. J. Virol. 88, 4679–4686. doi: 10.1128/JVI.03587-13
Wu, N., Gao, N., Fan, D., Wei, J., Zhang, J., and An, J. (2014). miR-223 inhibits dengue virus replication by negatively regulating the microtubule-destabilizing protein STMN1 in EAhy926 cells. Microbes Infect. 16, 911–922. doi: 10.1016/j.micinf.2014.08.011
Wu, Q., Wang, X., and Ding, S. W. (2010). Viral suppressors of RNA-based viral immunity: host targets. Cell Host Microbe 8, 12–15. doi: 10.1016/j.chom.2010.06.009
Wu, S., He, L., Li, Y., Wang, T., Feng, L., Jiang, L., et al. (2013). miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6. J. Infect. 67, 329–341. doi: 10.1016/j.jinf.2013.05.003
Yao, Y., Smith, L. P., Nair, V., and Watson, M. (2014). An avian retrovirus uses canonical expression and processing mechanisms to generate viral microRNA. J. Virol. 88, 2–9. doi: 10.1128/JVI.02921-13
Yin, Q., Wang, X., Roberts, C., Flemington, E. K., and Lasky, J. A. (2016). Methylation status and AP1 elements are involved in EBV-mediated miR-155 expression in EBV positive lymphoma cells. Virology 494, 158–167. doi: 10.1016/j.virol.2016.04.005
Zhang, Y., and Li, Y. K. (2013). MicroRNAs in the regulation of immune response against infections. J. Zhejiang Univ. Sci. B 14, 1–7. doi: 10.1631/jzus.B1200292
Zhang, Y., Yang, L., Wang, H., Zhang, G., and Sun, X. (2016). Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon-alpha receptor. Biochem. Biophys. Res. Commun. 478, 1436–1441. doi: 10.1016/j.bbrc.2016.08.142
Zheng, Y. H., Jeang, K. T., and Tokunaga, K. (2012). Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology 9:112. doi: 10.1186/1742-4690-9-112
Keywords: microRNAs, viral microRNAs, virus life cycle, gene expression, clinical perspectives
Citation: Bruscella P, Bottini S, Baudesson C, Pawlotsky J-M, Feray C and Trabucchi M (2017) Viruses and miRNAs: More Friends than Foes. Front. Microbiol. 8:824. doi: 10.3389/fmicb.2017.00824
Received: 02 March 2017; Accepted: 21 April 2017;
Published: 15 May 2017.
Edited by:
Andrea Masotti, Bambino Gesù Ospedale Pediatrico (IRCCS), ItalyReviewed by:
Noam Shomron, Tel Aviv University, IsraelAlessio Paone, Sapienza University of Rome, Italy
Lorena Bavia, Universidade Positivo, Brazil
Copyright © 2017 Bruscella, Bottini, Baudesson, Pawlotsky, Feray and Trabucchi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Patrice Bruscella, patrice.bruscella@inserm.fr Michele Trabucchi, Michele.TRABUCCHI@unice.fr